It is possible that MSB went into a TH and advised that is was a 'corporate update', not primarily because of the trial but to ascertain the reaction and decision from Novartis.
At this point it appears no official change from Novartis. Novartis will need to analyse the trial data and secondary endpoint data. Plus as some have indicated, MSB may have missed the 43% endpoint but perhaps it is say 30%, which would in fact be a good result.
The product hasnt necessarily failed in effectiveness but rather it has failed its set target.
Plenty of unkowns and from here plenty of both upside and downside possibilities.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-468
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |